N 3 (188) 2024. P. 79–84

MARKET RESEARCH OF THE RANGE OF MEDICINES FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS IN THE PHARMACEUTICAL MARKET OF UKRAINE

O. A. Stepanova, O. I. Bielyaieva, L. M. Unhurian, I. V. Vyshnytska,
I. S. Yashchuk, Ch. Yu. Voloshchuk

Odesa National Medical University, Odesa, Ukraine

DOI 10.32782/2226-2008-2024-3-13

The medical and social problem of postmenopausal osteoporosis has a significant financial burden on the health care system.

The purpose of the study. The purpose of the study is to examine medicines of subgroup M05B “Drugs affecting the structure and mineralization of bone tissue” in the pharmaceutical market of Ukraine and determine their physical availability to consumers.

Materials and methods of research. The materials of the study included medical and technological documents of postmenopausal osteoporosis, data from the State Register of Medicines of Ukraine (dated 01.02. 2024), the aggregator site tabletki.ua, the State Formulary of Medicines (issues 12-16), the National List of Essential Medicines, and the Register of Wholesale Prices.

To achieve the goal, we used content analysis, marketing, statistical, comparative, graphical and generalization methods.

Result and Conclusion. There are 41 registered medicines in Ukraine, of which more than 85% are foreign-made, mostly in the form of concentrate for solution for infusion. Discrepancies have been identified in the ratio of registered M05B medicines to the actual supply in pharmacies in Odesa, Kyiv and Lviv regions, which reduces the physical availability of medicines for patients. The State Formulary of Medicines averagely contains 40.4% of the medicines under study out of the total number of registered ones. The absence of drugs with zoledronic acid in the Register of Wholesale Prices has been established, which makes it impossible to procure them at the expense of state and local budgets. The National List of Essential Medicines includes zoledronic and ibandronic acids, which means that there is no state regulation of prices for other drugs of the investigated group in the retail and wholesale segment of the pharmaceutical market of Ukraine.

Key words: market research, postmenopause, osteoporosis, bisphosphonates, availability.

REFERENCES

  1. Kanis J.A., Norton N., Harvey N.C. et al. SCOPE 2021: a new scorecard for osteoporosis in Europe. Arch Osteoporos. 2021; 16:82 Available from: https://doi.org/10.1007/s11657-020-00871-9
  2. World Osteoporosis Day | Simple ways to prevent osteoporosis. 2019 Oct 20. Available from: https://www.who.int/ westernpacific/articles/item/simple-ways-to-prevent-osteoporosis
  3. Matushchak M.R. , Horoshko O.M., Zakharchuk O.O. , Ezhned M. A., Palamar A. O. Kliniko-ekonomichnyi analiz stanu farmatsevtychnoho zabezpechennia khvorykh z perelomamy vnaslidok osteoporozudoi: Ukrainskyi zhurnal medytsyny, biolohii ta sportu. 2018; Tom 4, 1 (17): 172–176 (іn Ukrainian). Available from: https:// doi.org/ 10.26693/jmbs04.01.172
  4. Grygorieva N., Kovalenko V., Коrzh М. et al Guideline for diagnostic, prevention and treatment of postmenopausal osteoporosis. PAIN, JOINTS, SPINE.2023; 13(3): 128–154. Available from: https://doi.org/10.22141/pjs.13.3.2023.378
  5. Menopauzalni porushennia ta inshi rozladyv perymenopauzalnomu periodi klinichna nastanova, zasnovana na dokazakh (іn Ukrainian). Available from: https://www.dec.gov.ua/mtd/menopauzalni-porushennya-ta-inshi-rozlady-v- perymenopauzalnomu-periodi/
  6. Shoback D, Rosen C. J, Black D.M, Cheung A.M, Murad M.Н, Eastell R. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update. The Journal of Clinical Endocrinology & Metabolism. 2020; 105(3): 587–594. Available from: https://doi.org/10.1210/clinem/dgaa048
  7. Clinical guideline for the prevention and treatment of osteoporosis 2021. Available from: https://www.nogg.oruk/full- guideline
  8. Rogers MJ, Mönkkönen J, Munoz MA. Molecular mechanisms of action of bisphosphonates and new insights into their effects outside the skeleton. Bone. 2020; 139:115493. doi: 10.1016/j.bone.2020.115493. Epub 2020 Jun 20. PMID: 32569873.
  9. Compston J. Practical guidance for the use of bisphosphonates in osteoporosis. Bone. 2020;136:115330. Available from: https://doi: 10.1016/j.bone.2020.115330.
  10. Matiashova N.O., Herasymova O.O. Farmakoekonomichnyi analiz likarskykh preparativ, yaki vplyvaiut na strukturu ta mineralizatsiiu kistok. Klinich. farmatsiia. 2019; 1(23); 56–61 (іn Ukrainian). Available from: https://doi: 10.24959/ cphj.19.1481
  11. Kompendium – likarski preparaty (іn Ukrainian). Available from: https://compendium.com.ua/
  12. WHO Collaborating Centre for Drug Statistics Methodology. Available from: https://atcddd.fhi.no/atc_ddd_index/?code=M 05&showdescription=no
  13. Derzhavnyi reiestr likarskykh zasobiv Ukrainy (іn Ukrainian). Available from: http://www.drlz.com.ua/
  14. ua — ahrehator aptek, medychnykh preparativ, tovariv dlia hihiieny, zdorovia ta krasy (іn Ukrainian). Available from: https://tabletki.ua/
  15. Derzhavnyi ekspertnyi tsentr MOZ Ukrainy (іn Ukrainian). Available from: https://www.dec.gov.ua/
  16. Natsionalnyi perelik osnovnykh likarskykh zasobiv (іn Ukrainian). Available from: https://zakon.rada.gov.ua/laws/ show/333-2009-%D0%BF#n15
  17. Postanova KMU vid 25 bereznia 2009 r. № 333 Deiaki pytannia derzhavnoho rehuliuvannia tsin na likarski zasoby ta vyroby medychnoho pryznachennia (іn Ukrainian). Available from: https://zakon.rada.gov.ua/laws/show/333-2009-%D0%BF#Text
  18. Reiestr optovo – vidpusknykh tsin na likarski zasoby stanom na 14.05.2024 (іn Ukrainian). Available from: https://moz.gov. ua/en/reestr-optovo-vidpusknih-cin-na-likarski-zasobi
View article PDF